Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 12/20 | 0.83 |
| ▸ | FLT1 | P17948 | 3/20 | 0.79 |
| ▸ | FBP1 | P09467 | 3/20 | 0.79 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.79 |
| ▸ | KDR | P35968 | 8/20 | 0.74 |
| ▸ | RET | P07949 | 4/20 | 0.69 |
| ▸ | SRC | P12931 | 4/20 | 0.69 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.69 |
| ▸ | GAK | O14976 | 3/20 | 0.69 |
| ▸ | ABL1 | P00519 | 3/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.69 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | RAF1 | P04049 | 2/20 | 0.69 |
| ▸ | CDK2 | P24941 | 2/20 | 0.69 |
| ▸ | ABL2 | P42684 | 2/20 | 0.69 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.69 |
| ▸ | PLK4 | O00444 | 1/20 | 0.69 |
| ▸ | CIT | O14578 | 1/20 | 0.69 |
| ▸ | AURKA | O14965 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL799667 | 0.97 | EGFR (0.78) | EGFRFLT1FBP1FGFR1KDR | |
| Hydrochloric Acid SCHEMBL8870869 | 0.96 | EGFR (0.76) | EGFRFLT1FBP1FGFR1KDR | |
| SCHEMBL31060707 | 0.91 | EGFR (1.00) | EGFRFLT1FBP1FGFR1KDR | |
| SCHEMBL5482883 | 0.91 | EGFR (1.00) | EGFRFLT1FBP1FGFR1KDR | |
| SCHEMBL8870965 | 0.90 | EGFR (0.81) | EGFRFLT1FBP1FGFR1KDR | |
| SCHEMBL2101009 | 0.90 | EGFR (0.81) | EGFRFLT1FBP1FGFR1KDR | |
| Hydrochloric Acid SCHEMBL5478587 | 0.90 | EGFR (0.97) | EGFRFLT1FBP1FGFR1KDR | |
| SCHEMBL19885292 | 0.89 | EGFR (0.74) | EGFRFLT1FBP1FGFR1KDR | |
| SCHEMBL8871648 | 0.89 | EGFR (0.78) | EGFRFLT1FBP1FGFR1KDR | |
| SCHEMBL22367416 | 0.88 | FBP1 (1.00) | EGFRFLT1FBP1FGFR1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5457105-A | anticancer use; e.g. 4-(3'-chloro-4'-fluoroanilino)-6,7-dimethoxyquinazoline (gefitinib) | ZENECA LIMITED (GB) | 1995-10-10 | — | — | US | claimed |
| US-20160303127-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | GENENTECH INC (US) | 2016-10-20 | — | — | US | disclosed |
| US-20150086545-A1 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | GENENTECH, INC. (US) | 2015-03-26 | — | — | US | disclosed |
| US-20150056207-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | GENENTECH INC (US) | 2015-02-26 | — | — | US | disclosed |
| US-20120251530-A1 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | SLIWKOWSKI MARK X (US) | 2012-10-04 | — | — | US | disclosed |
| US-20120189573-A1 | Methods of using death receptor agonists and EGFR inhibitors | GENENTECH, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-8163287-B2 | Combination therapy of her expressing tumors | GENENTECH, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110262436-A1 | TREATMENT METHOD | GENENTECH, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| EP-2344543-A2 | TREATMENT METHOD | Genentech, Inc. (US) | 2011-07-20 | — | — | EP | disclosed |
| US-20090226443-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | GENENTECH, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| EP-1853300-A2 | METHODS OF USING DEATH RECEPTOR AGONISTS AND EGFR INHIBITORS | Genentech, Inc. (US) | 2007-11-14 | — | — | EP | disclosed |
| WO-2007013950-A9 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | GENENTECH INC (US) | 2007-03-29 | — | — | WO | disclosed |
| WO-2007013950-A2 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | GENENTECH, INC. (US) | 2007-02-01 | — | — | WO | disclosed |
| US-20070020261-A1 | Combination therapy of her expressing tumors | GENENTECH, INC. | 2007-01-25 | — | — | US | disclosed |
| WO-2006089015-A2 | METHODS OF USING DEATH RECEPTOR AGONISTS AND EGFR INHIBITORS | GENENTECH, INC. (US) | 2006-08-24 | — | — | WO | disclosed |
| US-20060188498-A1 | Methods of using death receptor agonists and EGFR inhibitors | GENENTECH, INC. | 2006-08-24 | — | — | US | disclosed |
| US-5616582-A | Use as anticancer agents; e.g. gefitinib | ZENECA LIMITED (GB) | 1997-04-01 | — | — | US | disclosed |
| EP-0566226-B1 | Quinazoline derivatives | ZENECA LTD (GB) | 1995-11-08 | — | — | EP | disclosed |
| US-5457105-A | anticancer use; e.g. 4-(3'-chloro-4'-fluoroanilino)-6,7-dimethoxyquinazoline (gefitinib) | ZENECA LIMITED (GB) | 1995-10-10 | — | — | US | disclosed |
| EP-0566226-A1 | Quinazoline derivatives | ZENECA LIMITED (GB) | 1993-10-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120189573-A1 | Methods of using death receptor agonists and EGFR inhibitors | EGFR, ERBB4, TNFRSF9 | EGFR 1/4885FLT1 253/4885FBP1 3954/4885 |
| US-20150086545-A1 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | ERBB2, EGFR, ERBB3 | EGFR 2/4885FLT1 46/4885FBP1 2318/4885 |
| US-20060188498-A1 | Methods of using death receptor agonists and EGFR inhibitors | EGFR, ERBB4, TNFRSF9 | EGFR 1/4885FLT1 253/4885FBP1 3954/4885 |
| US-20070020261-A1 | Combination therapy of her expressing tumors | ERBB2, EGFR, ERBB3 | EGFR 2/4885FLT1 46/4885FBP1 2318/4885 |
| US-20090226443-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | MET, EGFR, ERBB2 | EGFR 2/4885FLT1 18/4885FBP1 3214/4885 |
| US-20160303127-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | MET, EGFR, ERBB2 | EGFR 2/4885FLT1 18/4885FBP1 3214/4885 |
| US-20110262436-A1 | TREATMENT METHOD | HGF, HDGF, FGF2 | EGFR 6/4885FLT1 86/4885FBP1 2775/4885 |
| US-20150056207-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | MET, EGFR, ERBB2 | EGFR 2/4885FLT1 18/4885FBP1 3214/4885 |
| US-20120251530-A1 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | ERBB2, EGFR, ERBB3 | EGFR 2/4885FLT1 46/4885FBP1 2318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.